TGFB1 and neoplasm: Tregs drawn by the tumor have higher suppressive properties compared to circulating Tregs and are able to inhibit the anti-tumor activity of other immune cells directly using cell–cell interactions or indirectly through synthesis and the secretion of mediators, e.g., TGF-β, interleukin 10 (IL-10) [50,51].